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INFECTIOUS DISEASE OUTCOMES RESEARCH
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ANTIBIOTIC PRESCRIBING VIA TELEPHONE: HOW OFTEN DOES IT OCCUR?
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OBJECTIVES: Antibiotic prescribing via telephonemay be associated with inappro-
priate antibiotic use and potential bacterial resistance, although limited data exist
regarding this practice. The purpose of this analysiswas to examine the prevalence
and patterns of telephone antibiotic prescribing. METHODS: Patients’ antibiotic
prescription data were retrieved from a large, Mid-Atlantic health system outpa-
tient electronic medical record from 2006-2010. Antibiotic prescriptions were cat-
egorized as initiated by telephone or office visit and by antibiotic classifications;
antibiotics for chronic usewere excluded. Practiceswere categorized as teaching or
private. Annual number of patients was calculated as a three-year running average
and patient data were censored on date of death, date of last activity plus 24
months, or January 1, 2011, whichever came earliest. Rates of telephone antibiotic
prescribing were calculated and stratified by practice type and antibiotic
classification. RESULTS: The analysis included 219,282 patient-years (pt-yrs), dur-
ing which 64,193 antibiotic prescriptions were generated. Overall antibiotic pre-
scribingwas 29.3/100 pt-yrs; 12.4% of the antibiotics were prescribed via telephone,
although 39.0% of these “telephone-antibiotic” patients had an office visit in the
prior 7 days. Antibiotic prescribing overall and via telephone was greater in private
practices (34.7/100 pt-yrs and 14.0%) compared with teaching practices (20.6/100
pt-yrs and 8.0%) (both P0.05). Macrolides (25.4%) and beta-lactams (22.9%) were
the most commonly prescribed antibiotic classes overall with macrolides and
quinolones most common via telephone. Approximately one-fifth of quinolone
prescriptions (20.1%) were prescribed via telephone, including 16.6% for newer
quinolones (levofloxacin or moxifloxacin). CONCLUSIONS: Prescribing via tele-
phone occurred in approximately one in eight antibiotic prescriptions and varied
by practice type and antibiotic classification. Significant numbers of prescriptions
for newer, broad spectrum antibiotics were generated telephonically. The fre-
quency and prescribing patterns associated with telephone antibiotic prescribing
in this population support the need for further study of its impact on antibiotic
resistance.
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OBJECTIVES: No large, randomized head-to-head comparison of atazanavir/
ritonavir (ATV/r) and darunavir /ritonavir (DRV/r) for first-line treatment of HIV-1 is
currently available. This study compares the efficacy of ATV/r and DRV/r at 48
weeks using a matching-adjusted indirect comparison. METHODS: Two similarly
designed randomized trials were identified. Individual patient-level data were
available for the CASTLE trial comparing ATV/r (n430) vs. lopinavir/r (LPV/r)
(n438), each in combination with tenofovir/emtricitabine (TDF/FTC); published
summary data were used from the ARTEMIS trial comparing DRV/r (n343) vs.
LPV/r (n346), each in combination with TDF/FTC. To adjust for cross-trial differ-
ences, CASTLE patients were re-weighted to match summary baseline character-
istics in ARTEMIS. The primary endpoint was virologic response (HIV-1 RNA50
copies/mL) at 48 weeks assessed using time to loss of virologic response (TLOVR),
and was compared between balanced ATV/r and DRV/r trial populations after
matching. As a negative control, outcomes in the two LPV/r arms were compared.
RESULTS: Data from all patients in the two trials were included. Before matching,
baseline characteristics differed significantly between CASTLE and ARTEMIS. CAS-
TLE had a higher proportion of patients with HIV-1 RNA100,000 copies/mL, a
lower proportion with CDC class C, and lower median CD4 cell count. Without
matching, a naïve comparison showed ATV/r-treated patients had a significantly
lower virologic response rate at week 48 than DRV/r-treated patients (78% vs. 84%,
p0.040). After matching, mean baseline characteristics were exactly balanced
between CASTLE and ARTEMIS, and virologic response to LPV/r was comparable
(77% vs. 78%, p0.811). There was no significant difference between ATV/r and
DRV/r in virologic response rate (80% vs. 84%, p0.138). CONCLUSIONS: After ad-
justing for cross-trial differences in baseline characteristics, the analysis suggests
that ATV/r and DRV/r, each in combination with TDF/FTC, are equally efficacious.
A randomized head-to-head trial will provide the gold standard of the comparative
efficacy between the two treatments.
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TRANSLATING OUTCOMES FROM A DYNAMIC TRANSMISSION MODEL FOR
VARICELLA VACCINATION TO COST-EFFECTIVENESS ESTIMATES: THE IMPACT
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OBJECTIVES: Compare three different analytic approaches to estimate the cost-
effectiveness of a varicella vaccination programme using clinical outcomes from a
dynamic transmission model. METHODS: An age-structured SIR (susceptible, in-
fectious, recovered) dynamic transmission model was developed to predict the
impact of routine infant vaccination on varicella incidence. Individuals transi-
tioned between S and I compartments based on UK force-of-infection data. Each
compartmentwas stratified into 8 age groups to track individuals as they aged over
time. Input parameters including force of infection, who-acquires-infection-from-
whom (WAIFW)matrix structure, vaccine efficacy, vaccine coverage, costs, QALYs,
and demographic data were based on published UK data. Themodel estimated the
incremental cost-effectiveness ratio (ICER) for the vaccination programme using
three analytic approaches: summing outcomes 1) for the entire population cumu-
latively over time (CumPop), 2) for the entire population for the steady-state year
(SSPop), and 3) for the lifetime of the first vaccinated birth cohort (Cohort). Costs
and QALYs were discounted at 3.5% per year. ICERs were compared for the three
analyses for different time horizons and vaccine coverage rates. RESULTS: The
vaccination programme reached a steady state after 75 years. For this timehorizon,
the incremental costs per QALY gained for the CumPop (£1,407) and SSPop (£868)
analyses were 47% and 68% lower than for the Cohort (£2,678) analysis. In the
CumPop and Cohort analyses, the ICER decreased as the model time horizon in-
creased and as vaccine coverage increased. The ICER for the CumPop analysis was
always lower than for the Cohort analysis; in the steady-state year, the ICER for the
SSPop analysis was the lowest. CONCLUSIONS: Cost-effectiveness estimates using
data from dynamic transmission models differ depending on the analytic ap-
proach, time horizon, and coverage rate used, with the two population approaches
yielding lower ICERs because they better capture the full population benefit of herd
protection.
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OBJECTIVES:To compareHCRU and costs between linezolid (LZD) and vancomycin
(VAN) using data from a clinical trial assessing the treatment of NP due to MRSA in
hospitalized adults. METHODS: A post-hoc analysis was conducted using data
from a multi-center trial (Wunderink et al, Clin Infect Dis 2012) to assess length of
treatment (LOT), length of stay (LOS), intensive care unit (ICU) days, mechanical
ventilator (MV) days, and associated costs in NP patients with culture-proven
MRSA [modified intent-to-treat (MITT) cohort]. HCRU was collected through end of
study (EOS; 7-30 days after end of treatment). Frequency and HCRU of moderate/
severe adverse events (MSAE) and renal failure were also assessed. RESULTS:MITT
patients (n448; 224 LZD/224 VAN) had mean (SD) age of 61.8(18.0) years, were
65.6% male, 68.8% white, with 63.1% from North America. At EOS, more LZD vs.
VAN had clinical success (54.8% vs. 44.9%; p0.049), 50.9% remained hospitalized.
No significant differences were found for HCRU or costs (LZD vs VAN):
LOT10.0(3.9) vs. 9.6(4.5) days; MV days8.3(9.3) vs. 8.1(9.1); ICU days10.1(8.8) vs.
10.6(8.7); LOS17.9(9.6) vs. 18.6(9.7) days. 310 patients developed1 MSAE and had
1.7 days longer LOS vs. patients without MSAE. 43 patients (9 LZD/34 VAN,
p0.0001) developed renal failure; renal failure patients had 4.2(p0.004),
3.5(p0.013), and 0.6(p0.74) days longer MV, ICU, and LOS vs. patients without
renal failure. Per patient total costs through EOSwere LZD $45,004 ($25,266) vs. VAN
$44,897 ($25,356). CONCLUSIONS: HCRU and costs were not significantly different
for patients treated with either LZD or VAN during the study. Higher drug acquisi-
tion costs of LZDmay be partially offset by fewer days in ICU and shorter LOS. LOS
is likely underestimated because 50% patients remained hospitalized at EOS
when LOSwas censored. LZD patientsweremore likely to have clinical success and
less likely to develop renal failure.
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FDA ACTIONS AGAINST HEALTH ECONOMIC PROMOTIONS, 2002-2011
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OBJECTIVES: To investigate FDA regulatory actions against drug company’s health
economic promotions from 2002 through mid 2011 to understand the types of
economic promotions the Agency considers false or misleading. METHODS: We
reviewed all warning letters and notices of violation (“untitled letters”) issued by
the FDA’s Division of Drug Marketing Advertising and Communications (DDMAC)
to pharmaceutical companies between January 2002 andAugust 2011.We searched
for and analyzed letters containing a violation related to “health economic promo-
tions,” defined according to one of several categories (e.g., implied claims of cost-
savings due to work productivity; economic claims containing unsupported state-
ments about effectiveness or safety). We also collected information on other
factors, such as the indication involved, and whether the letter referenced Section
114 of the Food and Drug Administration Modernization Act (FDAMA), which cre-
ated a different evidentiary standard for health economic promotions made to
formulary committees. RESULTS: Of 280 DDMAC letters sent to pharmaceutical
companies during the study period, 34 (12%) cited an economic violation. Themost
common type (found in 20 letters) was an unsupported implied claim of cost-
savings due to work productivity or functioning. The next most frequent types
included an economic claim containing an unsubstantiated comparative state-
ment of effectiveness, safety, or interchangeability (5 letters) and implied claims of
cost-savings to broader audiences than applicable (4 letters). Economic violations
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